<DOC>
	<DOC>NCT00185458</DOC>
	<brief_summary>The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age. The main area of interest in the study is the pattern of any vaginal bleeding that occurs.</brief_summary>
	<brief_title>Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Women with intact uterus, regular menstrual cycles and no previous or current climacteric symptoms. Pregnancy or lactation. Previous pelvic infections. Abnormal bleeding. Abnormal uterine cavity. Uterine polyps. Genital cancer. Liver diseases. Alcoholism or drug abuse.</criteria>
	<gender>Female</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>